Elutia Inc.

Contributing Author

Recent Articles by Elutia Inc.

Aug-18	Elutia Completes SimpliDerm Sale on Schedule, Adds $8 Million in Cash to Fund NXT-41x Through Full Commercial Launch ELUT -6.75% GlobeNewswire
Aug-13	Elutia Secures Up to $26 Million to Fund NXT-41x Through Commercial Launch; Reports Second Quarter 2026 Results ELUT +5.17% ELUT +9.38% GlobeNewswire
Aug-13	Elutia Secures $15 Million Loan Financing from Avenue Capital Group to Fund NXT-41x Launch in $1.5 Billion Plastic and Reconstructive Surgery Market ELUT +5.17% ELUT +9.38% GlobeNewswire
Jul-31	Elutia to Report Second Quarter 2026 Financial Results on Thursday, August 13, 2026 ELUT -5.33% GlobeNewswire
Jul-16	Elutia Signs Definitive Agreement to Sell SimpliDerm in Transaction Valued at up to $11 Million, Strengthening Balance Sheet Ahead of NXT-41x Launch ELUT GlobeNewswire
Jun-11	Elutia to Present at Planet MicroCap Showcase 2026 on June 17th ELUT -8.02% GlobeNewswire
May-18	Elutia Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) ELUT +6.80% GlobeNewswire
May-14	Elutia Reports First Quarter 2026 Results and Highlights NXT-41x Progress Toward $1.5 Billion U.S. Plastic and Reconstructive Surgery Market ELUT GlobeNewswire
May-14	Elutia to Present at the 16th Annual LD Micro Invitational on May 18th ELUT GlobeNewswire
Apr-30	Elutia to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026 ELUT GlobeNewswire
Mar-17	Elutia to Present at Sidoti's Small-Cap Virtual Investor Conference March 18-19 ELUT GlobeNewswire
Mar-13	Elutia Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) ELUT -6.09% GlobeNewswire
Mar-11	Elutia Reports Fourth Quarter and Full Year 2025 Financial Results; Initiates NXT-41 Regulatory Process ELUT ELUT +5.50% GlobeNewswire
Mar-04	Elutia Regains Compliance with Nasdaq Listing Requirements ELUT GlobeNewswire
Mar-02	Elutia Selects Pete Ligotti as CCO to Lead the Commercial Launch of NXT-41x and Transform Post-Mastectomy Care in the $1.5B U.S. Breast Surgery Market ELUT GlobeNewswire
Feb-25	Elutia to Report Fourth Quarter 2025 Financial Results on Wednesday, March 11, 2026 ELUT ELUT +5.50% GlobeNewswire
Feb-18	Where Purpose Meets Performance: Elutia Earns 2026 Great Place to Work Certification ELUT GlobeNewswire
Jan-12	Elutia Reports Preliminary Fourth Quarter 2025 Results, Strengthened Financial Position, and Upcoming NXT-41x Milestones ELUT GlobeNewswire
Jan-09	Elutia to Present at Global BioInnovation Forum on NXT-41x Biomatrix Program for Plastic and Reconstructive Surgery ELUT GlobeNewswire
Nov-06	Elutia Reports Third Quarter 2025 Financial Results; Closes $88 Million Sale of BioEnvelope Business to Boston Scientific Corporation; Funds NXT-41x Development ELUT GlobeNewswire
Oct-23	Elutia to Report Third Quarter 2025 Financial Results on Thursday, November 6, 2025 ELUT GlobeNewswire
Oct-14	Elutia to Present at the LD Micro Main Event XIX Conference on Tuesday, October 21 ELUT GlobeNewswire
Oct-10	Elutia Appoints Accomplished MedTech Veteran Guido J. Neels to Board of Directors ELUT GlobeNewswire
Oct-01	Elutia Announces Closing of BioEnvelope Business Sale to Boston Scientific Corporation for $88 Million ELUT GlobeNewswire
Sep-16	Elutia Announces Newly Published Clinical Data Demonstrating that Biologic Envelopes Support CIED Stabilization and Ease of Reoperation ELUT GlobeNewswire
Sep-09	Elutia Announces Sale of BioEnvelope Business to Boston Scientific Corporation for $88 Million ELUT -21.54% GlobeNewswire
Sep-04	Elutia Selected to Exhibit EluPro Antibiotic Eluting BioEnvelope at Vizient Innovative Technology Exchange ELUT GlobeNewswire
Aug-27	Elutia to Participate in Upcoming Investor Conferences ELUT -7.92% GlobeNewswire
Aug-14	Elutia Delivers Robust Growth on the Strength of EluPro Market Adoption ELUT ELUT -6.05% GlobeNewswire
Jul-31	Elutia to Report Second Quarter 2025 Financial Results on Thursday, August 14, 2025 ELUT GlobeNewswire
Jul-31	Dr. Michelle LeRoux Williams Earns Washington Business Journal's Medical Device Innovator Award ELUT GlobeNewswire
Jul-01	New Evidence Supports the Value of Elutia's Antibiotic-Eluting Platform for Implantable Devices ELUT +7.58% GlobeNewswire
May-28	Elutia Strengthens Drug-Eluting Biomatrix Platform with Peer-Reviewed Publication of Novel EluPro Testing Method ELUT GlobeNewswire
May-08	Elutia Announces Strong First Quarter 2025 Financial Results Driven by 84% Sequential Growth in EluPro Sales ELUT GlobeNewswire
May-01	Elutia Transitions to Direct Distribution of Its Cardiovascular Product Portfolio ELUT ELUT -7.69% GlobeNewswire
May-01	Elutia to Report First Quarter 2025 Financial Results on Thursday, May 8, 2025 ELUT GlobeNewswire

Elutia Inc.

Recent Articles by Elutia Inc.

Upgrade your Finviz experience